EUROAPI General Assembly: Approval of Resolutions and Perspectives

On May 11, 2023, the Combined General Meeting of EUROAPI shareholders was held in Paris under the chairmanship of Viviane Monges. All proposed resolutions, including the financial statements for the 2022 financial year and the ratification of Mattias Perjos as an independent director, were adopted. The Board of Directors remains dominated by independent members.

The event also confirmed the company's short- and medium-term outlook. EUROAPI also announced the resumption of full prostaglandin production in Budapest and a reorganization of its R&D with five technology platforms.

The API Solutions business continues to expand with the acquisition of new clients. In the CDMO sector, several projects have been signed, notably with Novéal and SQY Therapeutics.